Provided by Tiger Trade Technology Pte. Ltd.

Abeona Therapeutics

4.85
-0.1500-3.00%
Post-market: 5.100.2500+5.15%19:38 EST
Volume:1.01M
Turnover:4.97M
Market Cap:262.83M
PE:3.77
High:5.09
Open:5.04
Low:4.80
Close:5.00
52wk High:7.54
52wk Low:3.93
Shares:54.19M
Float Shares:38.26M
Volume Ratio:0.69
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.29
EPS(LYR):-1.5527
ROE:75.90%
ROA:-29.57%
PB:1.53
PE(LYR):-3.12

Loading ...

Abeona Therapeutics Appoints Mohamad Tabrizi as Chief Business Officer

Reuters
·
Dec 15

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

THOMSON REUTERS
·
Dec 15

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

GlobeNewswire
·
Dec 11

Abeona Therapeutics Treats First Patient With FDA-Approved ZEVASKYN Gene Therapy

Reuters
·
Dec 08

Abeona Therapeutics® Announces First Patient Treatment With Zevaskyn® Gene Therapy

THOMSON REUTERS
·
Dec 08

ABEO Acquires 86.43% Stake in VOGO

Reuters
·
Dec 04

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 01

Press Release: Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Dec 01

Director Mark Alvino Reports Sale of Abeona Therapeutics Inc. Common Shares

Reuters
·
Nov 15

Optimistic Buy Rating for Abeona Therapeutics Amid Promising ZEVASKYN Outlook and Favorable Market Conditions

TIPRANKS
·
Nov 13

Abeona Therapeutics: Resilient Path to Profitability with Strong Market Demand and Strategic Optimizations

TIPRANKS
·
Nov 13

Abeona Therapeutics price target lowered to $19 from $20 at Stifel

TIPRANKS
·
Nov 13

Abeona Therapeutics Shares Soar on Higher Demand for Zevaskyn

Dow Jones
·
Nov 13

Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)

TIPRANKS
·
Nov 12

Abeona Therapeutics sees cash runway for over two years

TIPRANKS
·
Nov 12

Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate

Benzinga
·
Nov 12

Abeona Therapeutics Q3 EPS USD -0.1 VS. Ibes Estimate USD -0.29

THOMSON REUTERS
·
Nov 12

Abeona Therapeutics Q3 Income From Operations USD -24.018 Million VS. Ibes Estimate USD -18.2 Million

THOMSON REUTERS
·
Nov 12

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

GlobeNewswire
·
Nov 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12